# Frank Schueler

> Frank Schueler is a seed investor at KIZOO Technology Capital backing Biotechnology. See 27 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [KIZOO Technology Capital](https://shizune.co/investors/profile/kizoo)
- Location: Karlsruhe, Germany
- Total investments: 27
- Last investment: Sep 2025
- Lead investor: 48%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/frankschueler
- Website: http://www.kizoo.com

Frank Schueler is a seed investor at KIZOO Technology Capital in Karlsruhe focused on Biotechnology and Health Care. Frank Schueler is Managing Director of Kizoo. ​Frank led the IPO of web.de, co-founded the Kizoo Venture Capital business with Michael and Matthias, and since then has helped numerous startups to grow. Among Franks board-level assignments, he is COO of the Forever Healthy Foundation, co-founder of the Undoing Aging science conference series, memberof the board of the SENS Research Foundation, Mountain View, California and on the executive board of Atevia AG, a public company for 16 years.​Previously, he was a strategy consultant with PriceWaterhouseCoopers. Frank holds a M.Sc. (New York) and a Dipl.-Wirtsch.-Ing. from Karlsruhe Institute of Technology (KIT), Germany.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 30% |
| Health Care | 5 | 19% |
| Therapeutics | 5 | 19% |
| Biopharma | 4 | 15% |
| Life Science | 3 | 11% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 12 | 44% |
| Funding Round | 3 | 11% |
| Series A | 2 | 7% |
| Series B | 2 | 7% |
| Series D | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 37% |
| Germany | 3 | 11% |
| Austria | 1 | 4% |
| United Kingdom | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cellvie | Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.Mitochondria are at the heart of complex life's origin. Likely a bacterium at the time, the would-be-organelle merged with a simple organism, entering into a symbiotic relationship: The mitochondria began supplying theenergy for elaborate cellular functions to evolve, while the organism provided the mitochondria with an environment to thrive. Today, mitochondria are found in all human cells, except for red blood cells. They take on a pivotal role in cellular fate, as they produce most of the energy (ATP) and are involved in a large number of cellular and metabolic processes. The density of the organelles is particularly high in cells requiring a lot of cellular energy - e.g. cardiomyocytes or brain cells.Mitochondria function, and hence energy supply to the cell, may be impaired due to acute insults (e.g. ischemia) or genetic disorders (e.g. LOHN).Researchers at Harvard University developed an approach for mitochondria augmentation and replacement to ameliorate the damages from ischemia-reperfusion injury. Ischemia is a lack of blood flow leading to an undersupply of oxygen and an impairment of mitochondria function. Reperfusion describes the re-introduction of blood flow, inducing an oversupply of oxygen. Both, ischemia and reperfusion, damage cells, with the mitochondria dysfunction being at the heart of the injury. The cascade of events, from ischemia to reperfusion, will eventually lead to cell death. The most prominent acute conditions associated with ischemia-reperfusion injury are heart attacks. At Cellvie, we are developing a means to transplant viable mitochondria into the compromised cells, to interrupt the said cascade of events, re-enabling the cells to turn oxygen into energy via the mitochondria. | $5M | Seed | Sep 09, 2025 |  |
| Cellvie | Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.Mitochondria are at the heart of complex life's origin. Likely a bacterium at the time, the would-be-organelle merged with a simple organism, entering into a symbiotic relationship: The mitochondria began supplying theenergy for elaborate cellular functions to evolve, while the organism provided the mitochondria with an environment to thrive. Today, mitochondria are found in all human cells, except for red blood cells. They take on a pivotal role in cellular fate, as they produce most of the energy (ATP) and are involved in a large number of cellular and metabolic processes. The density of the organelles is particularly high in cells requiring a lot of cellular energy - e.g. cardiomyocytes or brain cells.Mitochondria function, and hence energy supply to the cell, may be impaired due to acute insults (e.g. ischemia) or genetic disorders (e.g. LOHN).Researchers at Harvard University developed an approach for mitochondria augmentation and replacement to ameliorate the damages from ischemia-reperfusion injury. Ischemia is a lack of blood flow leading to an undersupply of oxygen and an impairment of mitochondria function. Reperfusion describes the re-introduction of blood flow, inducing an oversupply of oxygen. Both, ischemia and reperfusion, damage cells, with the mitochondria dysfunction being at the heart of the injury. The cascade of events, from ischemia to reperfusion, will eventually lead to cell death. The most prominent acute conditions associated with ischemia-reperfusion injury are heart attacks. At Cellvie, we are developing a means to transplant viable mitochondria into the compromised cells, to interrupt the said cascade of events, re-enabling the cells to turn oxygen into energy via the mitochondria. | $5.5M | Seed | Feb 06, 2023 |  |
| Mogling Bio | Mogling Bio is developing novel pharmacological approaches to rejuvenate old stem cells. |  | Seed | Oct 26, 2022 |  |
| Elastrin Therapeutics | Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work.The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improvesthe efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. | $10M |  | Apr 07, 2022 |  |
| Elastrin Therapeutics | Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work.The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improvesthe efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. | $10M | Seed | Apr 07, 2022 |  |
| Cyclarity Therapeutics | Underdog Pharmaceuticals is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis,hypercholesterolemia, heart failure, and macular degeneration.Its products are based on novel derivatives of a well-known, safe compound, and a new way of looking at cardiovascular disease created through a SENS Research Foundation program. | $10M | Seed | Sep 23, 2021 |  |
| Staffbase | Staffbase provides an internal communications platform to help companies and their employees work together toward a common goal. Staffbase supports industry leaders with their own branded app to engage their diverse, disconnected, and distributed workforce. The company was founded in 2014 and is headquartered in Chemnitz with offices in Dresden,Cologne, and New York. | $143.6M | Series D | Mar 29, 2021 |  |
| Elastrin Therapeutics | Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work.The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improvesthe efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. | $2.5M | Seed | Mar 04, 2021 |  |
| Cellvie | Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.Mitochondria are at the heart of complex life's origin. Likely a bacterium at the time, the would-be-organelle merged with a simple organism, entering into a symbiotic relationship: The mitochondria began supplying theenergy for elaborate cellular functions to evolve, while the organism provided the mitochondria with an environment to thrive. Today, mitochondria are found in all human cells, except for red blood cells. They take on a pivotal role in cellular fate, as they produce most of the energy (ATP) and are involved in a large number of cellular and metabolic processes. The density of the organelles is particularly high in cells requiring a lot of cellular energy - e.g. cardiomyocytes or brain cells.Mitochondria function, and hence energy supply to the cell, may be impaired due to acute insults (e.g. ischemia) or genetic disorders (e.g. LOHN).Researchers at Harvard University developed an approach for mitochondria augmentation and replacement to ameliorate the damages from ischemia-reperfusion injury. Ischemia is a lack of blood flow leading to an undersupply of oxygen and an impairment of mitochondria function. Reperfusion describes the re-introduction of blood flow, inducing an oversupply of oxygen. Both, ischemia and reperfusion, damage cells, with the mitochondria dysfunction being at the heart of the injury. The cascade of events, from ischemia to reperfusion, will eventually lead to cell death. The most prominent acute conditions associated with ischemia-reperfusion injury are heart attacks. At Cellvie, we are developing a means to transplant viable mitochondria into the compromised cells, to interrupt the said cascade of events, re-enabling the cells to turn oxygen into energy via the mitochondria. | $5M | Seed | Jan 25, 2021 |  |
| Elevian | Elevian’s founders discovered circulating blood factors that regulate aging, including GDF11, which broadly stimulate regeneration of brain, heart, pancreas, muscle, and other tissues. Elevian is developing therapeutics that stimulate regenerative capacity, to treat and prevent age-related disease. | $15M | Seed | Nov 24, 2020 |  |

10 of 27 investments shown.

## Co-investors
- [Runa Capital](https://shizune.co/investors/profile/runa-capital) — VC Fund, 3 deals together
- [Capnamic](https://shizune.co/investors/profile/capnamic-ventures) — VC Fund, 2 deals together
- [General Atlantic](https://shizune.co/investors/profile/general-atlantic) — VC Fund, 2 deals together
- [Point Nine](https://shizune.co/investors/profile/point-nine-capital) — VC Fund, 2 deals together
- [SC Launch, Inc.](https://shizune.co/investors/profile/sc-launch) — VC Fund, 2 deals together
- [Taiho Ventures](https://shizune.co/investors/profile/taiho-ventures-2) — VC Fund, 2 deals together

## About KIZOO Technology Capital

VC Fund · Karlsruhe, Germany

KIZOO provides mentoring, seed and early-stage financing with a focus on rejuvenation biotech. Having been entrepreneurs, VCs and mentors in both, high growth tech and biotech companies theirselves for many years with multiple exits and massive value created for the founders, they now bring this experience to the emerging field of rejuvenationbiotech - a young industry that will eventually become much bigger than today's largest technology markets. ​ As part of the Forever Healthy Group, they directly support the creation of startups that turn research on the root causes of aging into therapies and services for humans. ​ Forever Healthy's other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conference.

3 contacts available at KIZOO Technology Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Frank Schueler | Managing Director | https://shizune.co/investors/profile/frank-schler |
| Michael Greve | Owner | https://shizune.co/investors/profile/michael-greve |
| Matthias Hornberger | CFO | https://shizune.co/investors/profile/matthias-hornberger |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Frank Schueler invest in?

Frank Schueler invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Funding Round stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Frank Schueler last invest?

The most recent investment recorded for Frank Schueler closed in Sep 2025. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co